EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY 4.0

Acute kidney injury in Staphylococcus aureus bacteraemia: a recurrent events analysis

David T P Buis, Thomas W van der Vaart, Asna Mohan, Jan M Prins, Jan T M van der Meer, Marc J M Bonten, Lily Jakulj, Cornelis H van Werkhoven, Kim C E Sigaloff

Clinical Microbiology and Infection · 2024-10 · 30 (10) · 1270-1275

DOI: 10.1016/j.cmi.2024.06.017 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Clinical Microbiology and Infection, 2024-10. Verfasst von David T P Buis und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Amsterdam UMC Location Vrije Universiteit Amsterdam, Amsterdam, the Netherlands; Amsterdam Institute for Infection a…. Hauptthemen laut MEDLINE: Bacteremia, Acute Kidney Injury, Staphylococcal Infections, Staphylococcus aureus. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: ZonMw.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVES: To estimate risk factors for acute kidney injury (AKI) and the effect of AKI on mortality in Staphylococcus aureus bacteraemia, while taking into account recurrent AKI episodes, competing risks, time-varying variables, and time-varying effects. METHODS: We performed an unplanned analysis using data from a multicentre cohort study of patients with Staphylococcus aureus bacteraemia (SAB). The primary outcome was cumulative incidence of AKI, according to Kidney Disease Improving Global Outcomes definitions. RESULTS: We included 453 patients in this study of whom 194 (43%) patients experienced one or more AKI episodes. Age (hazard ratio (HR) 1.013, 95% CI 1.001-1.024), Charlson comorbidity index (HR 1.07, 95% CI 1.01-1.14), prior chronic kidney disease (HR 1.76, 95% CI 1.28-2.42), septic shock (HR 3.28, 95% CI 2.31-4.66), persistent bacteraemia (HR 1.53, 95% CI 1.08-2.17), and vancomycin therapy (HR 1.80, 95% CI 1.05-3.09) were independently associated with AKI, but flucloxacillin, cefazolin, rifampicin, and aminoglycoside therapy were not. After adjustment for confounders and immortal time bias, AKI was associated with an increased risk of 90-day mortality (HR 4.26, 95% CI 2.91-6.23). DISCUSSION: The incidence of AKI in SAB is high and a substantial proportion of patients develop recurrent episodes of AKI after recovery. AKI is specifically linked to the use of vancomycin and not to anti-staphylococcal penicillins. The clinical outcome of patients with SAB complicated by AKI is worse than previously estimated.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BacteremiaAcute Kidney InjuryStaphylococcal InfectionsStaphylococcus aureusHumansMaleFemaleAgedMiddle AgedRisk FactorsIncidenceRecurrenceAnti-Bacterial AgentsCohort StudiesAged, 80 and overVancomycin

Stichwörter der Autor:innen

Acute kidney injuryAnti-staphylococcal penicillinsClinical epidemiologyCohort studyStaphylococcus aureus bacteraemia

Substanzen

Anti-Bacterial AgentsVancomycin

Autor:innen und Institutionen

  • Department of Internal Medicine, Amsterdam UMC Location Vrije Universiteit Amsterdam, Amsterdam, the Netherlands; Amsterdam Institute for Infection and Immunity, Amsterdam, the Netherlands. Electronic address: d.t.p.bui…
  • Amsterdam Institute for Infection and Immunity, Amsterdam, the Netherlands; Department of Internal Medicine, Amsterdam UMC Location Universiteit van Amsterdam, Amsterdam, the Netherlands; Julius Center for Health Scienc…
  • Department of Internal Medicine, Amsterdam UMC Location Vrije Universiteit Amsterdam, Amsterdam, the Netherlands; Amsterdam Institute for Infection and Immunity, Amsterdam, the Netherlands.
  • Department of Internal Medicine, Amsterdam UMC Location Vrije Universiteit Amsterdam, Amsterdam, the Netherlands.
  • Amsterdam Institute for Infection and Immunity, Amsterdam, the Netherlands; Department of Internal Medicine, Amsterdam UMC Location Universiteit van Amsterdam, Amsterdam, the Netherlands.
  • Julius Center for Health Sciences and Primary Care, UMC Utrecht, Utrecht University, Utrecht, the Netherlands; European Clinical Research Alliance on Infectious Diseases, Utrecht, the Netherlands.

Förderung

  • ZonMw

Zitieren

APA

Buis, D. T. P., van der Vaart, T. W., Mohan, A., Prins, J. M., van der Meer, J. T. M., Bonten, M. J. M., Jakulj, L., van Werkhoven, C. H., & Sigaloff, K. C. E. (2024). Acute kidney injury in Staphylococcus aureus bacteraemia: a recurrent events analysis. Clinical Microbiology and Infection, 30(10), 1270-1275. https://doi.org/10.1016/j.cmi.2024.06.017

Vancouver

Buis DTP, van der Vaart TW, Mohan A, Prins JM, van der Meer JTM, Bonten MJM, et al. Acute kidney injury in Staphylococcus aureus bacteraemia: a recurrent events analysis. Clinical Microbiology and Infection. 2024;30(10):1270-1275. doi:10.1016/j.cmi.2024.06.017

BibTeX
@article{Buis2024,
  author = {Buis, David T P and van der Vaart, Thomas W and Mohan, Asna and Prins, Jan M and van der Meer, Jan T M and Bonten, Marc J M and Jakulj, Lily and van Werkhoven, Cornelis H and Sigaloff, Kim C E},
  title = {Acute kidney injury in Staphylococcus aureus bacteraemia: a recurrent events analysis},
  journal = {Clinical Microbiology and Infection},
  year = {2024},
  volume = {30},
  number = {10},
  pages = {1270--1275},
  doi = {10.1016/j.cmi.2024.06.017}
}
Kostenlos starten →